These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27216065)

  • 21. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
    Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
    Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
    [No Abstract]   [Full Text] [Related]  

  • 23. Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method.
    Robledo J; Mejia GI; Paniagua L; Martin A; Guzmán A
    Int J Tuberc Lung Dis; 2008 Dec; 12(12):1482-4. PubMed ID: 19017461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
    Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
    Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
    Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
    Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
    J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
    De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
    Zhang N; Strydom N; Tyagi S; Soni H; Tasneen R; Nuermberger EL; Savic RM
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
    Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
    Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.
    Hillemann D; Rüsch-Gerdes S; Richter E
    J Clin Microbiol; 2007 Aug; 45(8):2635-40. PubMed ID: 17537937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey.
    Aslan G; Tezcan S; Serin MS; Emekdas G
    Jpn J Infect Dis; 2008 Jul; 61(4):255-60. PubMed ID: 18653964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure.
    Hu Y; Pertinez H; Liu Y; Davies G; Coates A
    J Antimicrob Chemother; 2019 Jun; 74(6):1627-1633. PubMed ID: 30789209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.